Dinutuximab

Advances in Risk Classification and Treatment Strategies for Neuroblastoma

(2015) Navin R. Pinto et al.   JOURNAL OF CLINICAL ONCOLOGY

Additional Therapies to Improve Metastatic Response to Induction Therapy in Children With High-risk Neuroblastoma

(2015) Dominik Schrey et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma

(2014) Ami V. Desai et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Airway and Lung Remodelling in Chronic Pulmonary Obstructive Disease: A Role for Muscarinic Receptor Antagonists?

(2014) Michael Roth   DRUGS

Clinical Ascertainment of Health Outcomes Among Adults Treated for Childhood Cancer

(2013) Melissa M. Hudson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Long-term follow-up of children with high-risk neuroblastoma: The ENSG5 trial experience

(2013) Lucas Moreno et al.   PEDIATRIC BLOOD & CANCER

Anti-GD2 Antibody Therapy for GD2-Expressing Tumors

(2010) F. Navid et al.   CURRENT CANCER DRUG TARGETS

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

(2010) Alice L. Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study

(2009) Katherine K. Matthay et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of ch14.18 With Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-2 in Children With Neuroblastoma After Autologous Bone Marrow Transplantation or Stem-Cell Rescue: A Report From the Children's Oncology Group

(2008) Andrew L. Gilman et al.   JOURNAL OF CLINICAL ONCOLOGY